A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-...
Saved in:
| Published in | Journal of clinical microbiology Vol. 59; no. 4 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
19.03.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies.
Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients. |
|---|---|
| AbstractList | Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients.Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients. Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients. Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus neutralization test (sVNT), compared directly with eight SARS-CoV-2 IgG serology and two live-cell neutralization tests, gives similar or improved accuracy for qualitative delineation between positive and negative individuals in a fast, scalable, and high-throughput assay. The combined data support the cPass sVNT as a tool for highly accurate SARS-CoV-2 immunity surveillance of infected/recovered and/or vaccinated individuals as well as drug and convalescent-phase donor screening. The data also preview a novel application for the cPass sVNT in calibrating the stringency of live-cell neutralization tests and its use in longitudinal testing of recovered and/or vaccinated patients. |
| Author | Annen, Kyle Taylor, Sean C. Kanji, Jamil N. Huey, Leah Knight, Vijaya McCarthy, Mary K. Morrison, Thomas E. Charlton, Carmen L. Bailey, Ashley DomBourian, Melkon G. Hurst, Beth |
| Author_xml | – sequence: 1 givenname: Sean C. orcidid: 0000-0003-3411-0673 surname: Taylor fullname: Taylor, Sean C. organization: GenScript USA Inc., Piscataway, New Jersey, USA – sequence: 2 givenname: Beth surname: Hurst fullname: Hurst, Beth organization: Cayman Chemical, Ann Arbor, Michigan, USA – sequence: 3 givenname: Carmen L. orcidid: 0000-0002-9129-5136 surname: Charlton fullname: Charlton, Carmen L. organization: Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada – sequence: 4 givenname: Ashley surname: Bailey fullname: Bailey, Ashley organization: Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada – sequence: 5 givenname: Jamil N. surname: Kanji fullname: Kanji, Jamil N. organization: Public Health Laboratory, Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, Edmonton, AB, Canada, Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada – sequence: 6 givenname: Mary K. surname: McCarthy fullname: McCarthy, Mary K. organization: Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA – sequence: 7 givenname: Thomas E. surname: Morrison fullname: Morrison, Thomas E. organization: Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA – sequence: 8 givenname: Leah surname: Huey fullname: Huey, Leah organization: Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA, Department of Pediatrics, Children’s Hospital Colorado Anschutz Medical Campus, Aurora, Colorado, USA – sequence: 9 givenname: Kyle surname: Annen fullname: Annen, Kyle organization: Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA, Department of Pathology and Laboratory Medicine, Children’s Hospital Colorado Anschutz Medical Campus, Aurora, Colorado, USA – sequence: 10 givenname: Melkon G. surname: DomBourian fullname: DomBourian, Melkon G. organization: Department of Pathology and Laboratory Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA, Department of Pathology and Laboratory Medicine, Children’s Hospital Colorado Anschutz Medical Campus, Aurora, Colorado, USA – sequence: 11 givenname: Vijaya surname: Knight fullname: Knight, Vijaya organization: Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA, Department of Pediatrics, Children’s Hospital Colorado Anschutz Medical Campus, Aurora, Colorado, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33500361$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1vEzEQhi1URNPCjTPyESRc_LXOLgekVVpoUflQExA3y7s7Tl1t7GDvFgX-PE5TKkBwsuR55tHMvAdozwcPCD1m9IgxXr54O3t3RLkUJeH0HpowWpVEKfplD00orQrCmJjuo4OUrihlUhbFA7QvREGpUGyCftT4PXzD8_piTmbhM-H4eDQ9-TjGdUiA5xBDH5YbvIA0vMSnbnnZb3DdtmM0A-Azb6EdXPB4EU3r_BIb32XhOETTu-_bj9oPrgndBl9AWgefnccw7JoeovvW9Ake3b6H6NPrk8XslJx_eHM2q8-JkaUcSFcKLnhTdExC0ynbSMGqzlo7LYUqIBearoVGgOLUsM7KSjCqQBpmrFKyE4fo1c67HpsVZNZvx9Pr6FYmbnQwTv9Z8e5SL8O1LmnFp5xmwdNbQQxfx3wJvXKphb43HsKYNJclU6Kkqsrosx1q0orrqzBGn1fTjOptWDqHpW_C0jfaJ7_PdTfQr3Qy8HwHtDGkFMHeIf_x8b_w1g1me-m8lev_3fQTb6exUA |
| CitedBy_id | crossref_primary_10_1093_rheumatology_keac036 crossref_primary_10_1128_JCM_01105_21 crossref_primary_10_1016_j_btre_2023_e00796 crossref_primary_10_1007_s12033_022_00563_4 crossref_primary_10_1111_trf_16714 crossref_primary_10_1007_s11596_021_2470_7 crossref_primary_10_1016_j_jviromet_2022_114569 crossref_primary_10_1016_j_vaccine_2021_07_098 crossref_primary_10_1016_j_jviromet_2023_114728 crossref_primary_10_1136_annrheumdis_2021_221916 crossref_primary_10_1038_s41467_022_33042_0 crossref_primary_10_3390_vaccines9121379 crossref_primary_10_1016_j_vaccine_2022_02_044 crossref_primary_10_1093_rheumatology_keac301 crossref_primary_10_1016_j_mjafi_2024_05_014 crossref_primary_10_1016_j_ijid_2021_05_080 crossref_primary_10_3389_fimmu_2022_859019 crossref_primary_10_3390_jcm10102128 crossref_primary_10_1136_annrheumdis_2021_220272 crossref_primary_10_3389_fmicb_2022_893801 crossref_primary_10_1038_s41467_022_35668_6 crossref_primary_10_3390_ani14192829 crossref_primary_10_1038_s41591_024_02955_2 crossref_primary_10_1038_s41598_022_21317_x crossref_primary_10_3390_v14102118 crossref_primary_10_1016_j_annepidem_2024_12_008 crossref_primary_10_3390_vaccines11121832 crossref_primary_10_3390_vaccines9101139 crossref_primary_10_1038_s41591_021_01469_5 crossref_primary_10_1371_journal_ppat_1012624 crossref_primary_10_2139_ssrn_4000668 crossref_primary_10_3390_pathogens11020171 crossref_primary_10_1021_acs_analchem_2c03193 crossref_primary_10_4049_jimmunol_2100036 crossref_primary_10_1136_annrheumdis_2021_221735 crossref_primary_10_1093_ndt_gfac018 crossref_primary_10_1186_s12985_024_02546_0 crossref_primary_10_1016_S2665_9913_21_00327_1 crossref_primary_10_1186_s12979_023_00368_2 crossref_primary_10_1002_jmv_29329 crossref_primary_10_1128_Spectrum_00087_21 crossref_primary_10_3390_ijms241914965 crossref_primary_10_1007_s10067_022_06134_x crossref_primary_10_3390_v14050946 crossref_primary_10_5858_arpa_2021_0213_SA crossref_primary_10_3390_vaccines12080914 crossref_primary_10_1093_jmcb_mjac023 crossref_primary_10_1186_s12979_024_00444_1 crossref_primary_10_1016_j_bsheal_2024_03_005 crossref_primary_10_3389_fimmu_2022_915001 crossref_primary_10_1002_acr_24824 crossref_primary_10_1016_j_aca_2021_339144 crossref_primary_10_3390_vaccines11091411 crossref_primary_10_3390_v16020187 crossref_primary_10_1136_annrheumdis_2021_220898 crossref_primary_10_1111_ajt_16766 crossref_primary_10_3390_v13040655 crossref_primary_10_3346_jkms_2021_36_e250 crossref_primary_10_1097_TP_0000000000004596 crossref_primary_10_1136_ard_2022_222689 crossref_primary_10_2139_ssrn_4005776 crossref_primary_10_3390_v13101972 crossref_primary_10_1016_j_jvacx_2023_100334 crossref_primary_10_3389_fimmu_2023_1187880 crossref_primary_10_1155_2023_1318901 crossref_primary_10_3390_microorganisms10102067 crossref_primary_10_1093_infdis_jiac035 crossref_primary_10_3390_vaccines9070742 crossref_primary_10_1016_j_jim_2022_113258 crossref_primary_10_1002_jcla_23921 crossref_primary_10_1016_j_vaccine_2021_08_022 crossref_primary_10_1016_j_vas_2024_100408 crossref_primary_10_3390_v13122405 crossref_primary_10_1038_s41598_025_90730_9 crossref_primary_10_1016_j_clinsp_2022_100150 crossref_primary_10_1093_rheumatology_keab773 crossref_primary_10_1093_rheumatology_keac105 crossref_primary_10_1016_j_jcv_2022_105169 crossref_primary_10_1128_Spectrum_00291_21 crossref_primary_10_1128_JCM_01717_21 crossref_primary_10_1128_spectrum_02314_22 crossref_primary_10_1136_annrheumdis_2021_222096 crossref_primary_10_1016_S2352_3018_22_00033_9 crossref_primary_10_7326_M21_3480 crossref_primary_10_1093_rheumatology_kead031 crossref_primary_10_3389_fcimb_2022_822599 crossref_primary_10_3390_v16010091 crossref_primary_10_1590_s1678_9946202163083 crossref_primary_10_1016_j_isci_2024_109123 crossref_primary_10_3390_diagnostics14192209 crossref_primary_10_1016_j_ijid_2022_08_022 crossref_primary_10_3390_v14071560 crossref_primary_10_1128_spectrum_01402_21 crossref_primary_10_3390_jcm10132844 crossref_primary_10_1016_j_biomaterials_2022_121694 crossref_primary_10_1007_s10900_022_01142_z crossref_primary_10_2139_ssrn_3928503 crossref_primary_10_3390_antib13030078 crossref_primary_10_3390_diagnostics11122193 crossref_primary_10_1038_s41598_024_58597_4 crossref_primary_10_1111_voxs_12644 crossref_primary_10_1016_j_jcvp_2021_100044 crossref_primary_10_3389_fneph_2022_926635 crossref_primary_10_1128_spectrum_02669_22 crossref_primary_10_1111_imcb_12539 crossref_primary_10_1177_09612033221102073 |
| Cites_doi | 10.4049/jimmunol.158.3.1446 10.1101/2020.06.26.173765 10.1093/ajcp/aqaa082 10.1038/s41564-020-0761-6 10.1038/s41577-020-0358-6 10.1016/S0140-6736(20)31252-6 10.1093/cid/ciaa619 10.1002/rmv.2106 10.1136/bmj.m2516 10.1038/s41587-020-0631-z 10.1128/JVI.02274-10 10.1126/sciimmunol.abc8413 10.1111/imm.13222 10.1038/s41467-020-18319-6 10.1016/j.jcv.2020.104394 10.1038/s41587-020-0659-0 10.1073/pnas.86.21.8392 10.1016/j.immuni.2020.03.007 10.1021/la903769c 10.1016/j.jim.2013.11.014 10.1056/NEJMoa2022483 10.1016/j.antiviral.2020.104820 10.1016/j.bbapap.2014.12.001 10.1016/j.mayocp.2020.04.004 10.1529/biophysj.104.051797 10.1128/JCM.01361-20 10.1371/journal.pntd.0002952 10.1186/1743-422X-7-299 10.1101/2020.07.31.230730 10.3390/v12050513 10.1093/infdis/jiaa673 10.1016/j.cell.2020.05.025 10.3390/v12060582 10.1128/JCM.02504-20 10.1016/j.pathol.2020.09.007 10.1016/j.jcv.2015.05.022 10.4414/smw.2020.20225 10.1038/s41586-020-2012-7 10.1016/j.hlpt.2020.04.010 10.1038/s41586-020-2349-y |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Taylor et al. Copyright © 2021 Taylor et al. 2021 Taylor et al. |
| Copyright_xml | – notice: Copyright © 2021 Taylor et al. – notice: Copyright © 2021 Taylor et al. 2021 Taylor et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1128/JCM.02438-20 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1098-660X |
| Editor | Hayden, Randall |
| Editor_xml | – sequence: 1 givenname: Randall surname: Hayden fullname: Hayden, Randall |
| ExternalDocumentID | PMC8092720 02438-20 33500361 10_1128_JCM_02438_20 |
| Genre | Journal Article |
| GroupedDBID | --- .55 0R~ 18M 29K 2WC 39C 4.4 53G 5GY 5RE 5VS AAGFI AAYXX ABOCM ABPPZ ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 D-I DIK DU5 E3Z EBS F5P FRP GX1 H13 HYE HZ~ KQ8 L7B O9- OK1 P2P P6G RHI RNS RPM RSF TR2 W8F WOQ X7M ZCA ~KM NPM - 0R 55 ABFLS ADACO BXI HZ KM RHF UCJ ZA5 7X8 5PM |
| ID | FETCH-LOGICAL-a484t-d83232b5d14ebd6fb4319dfff78365eb5dbdceb3e620a1df493106e4a1af664d3 |
| ISSN | 0095-1137 1098-660X |
| IngestDate | Thu Aug 21 14:32:09 EDT 2025 Fri Jul 11 11:58:42 EDT 2025 Tue Dec 28 13:59:21 EST 2021 Thu Apr 03 07:09:24 EDT 2025 Tue Jul 01 00:43:25 EDT 2025 Thu Apr 24 22:59:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | neutralizing antibodies SARS-CoV-2 vaccines serology ELISA |
| Language | English |
| License | Copyright © 2021 Taylor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a484t-d83232b5d14ebd6fb4319dfff78365eb5dbdceb3e620a1df493106e4a1af664d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE, Huey L, Annen K, DomBourian MG, Knight V. 2021. A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection. J Clin Microbiol 59:e02438-20. https://doi.org/10.1128/JCM.02438-20. |
| ORCID | 0000-0002-9129-5136 0000-0003-3411-0673 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8092720 |
| PMID | 33500361 |
| PQID | 2481638069 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8092720 proquest_miscellaneous_2481638069 asm2_journals_10_1128_JCM_02438_20 pubmed_primary_33500361 crossref_primary_10_1128_JCM_02438_20 crossref_citationtrail_10_1128_JCM_02438_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20210319 |
| PublicationDateYYYYMMDD | 2021-03-19 |
| PublicationDate_xml | – month: 3 year: 2021 text: 20210319 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Journal of clinical microbiology |
| PublicationTitleAbbrev | J Clin Microbiol |
| PublicationTitleAlternate | J Clin Microbiol |
| PublicationYear | 2021 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | Centers for Disease Control and Prevention (e_1_3_1_24_2) 2020 e_1_3_1_21_2 e_1_3_1_43_2 e_1_3_1_22_2 e_1_3_1_44_2 e_1_3_1_23_2 e_1_3_1_8_2 e_1_3_1_7_2 e_1_3_1_40_2 e_1_3_1_41_2 e_1_3_1_9_2 e_1_3_1_20_2 e_1_3_1_42_2 e_1_3_1_4_2 e_1_3_1_29_2 e_1_3_1_3_2 Brotherhood L (e_1_3_1_2_2) 2020 e_1_3_1_6_2 e_1_3_1_5_2 e_1_3_1_25_2 e_1_3_1_26_2 e_1_3_1_27_2 e_1_3_1_28_2 Lee SH (e_1_3_1_31_2) 2020; 2 e_1_3_1_32_2 e_1_3_1_33_2 Mannik M (e_1_3_1_16_2) 1997; 158 e_1_3_1_34_2 e_1_3_1_35_2 e_1_3_1_13_2 e_1_3_1_12_2 e_1_3_1_11_2 e_1_3_1_30_2 e_1_3_1_10_2 e_1_3_1_17_2 e_1_3_1_15_2 e_1_3_1_14_2 e_1_3_1_36_2 e_1_3_1_37_2 e_1_3_1_19_2 e_1_3_1_38_2 e_1_3_1_18_2 e_1_3_1_39_2 Brotherhood, L, Kircher, P, Santos, C, Tertilt, M (B1) 2020 Raffaini, G, Ganazzoli, F (B12) 2010; 26 Vogels, CBF, Brito, AF, Wyllie, AL, Fauver, JR, Ott, IM, Kalinich, CC, Petrone, ME, Casanovas-Massana, A, Muenker, MC, Moore, AJ, Klein, J, Lu, P, Lu-Culligan, A, Jiang, X, Kim, DJ, Kudo, E, Mao, T, Moriyama, M, Oh, JE, Park, A, Silva, J, Song, E, Takahashi, T, Taura, M, Tokuyama, M, Venkataraman, A, Weizman, O-E, Wong, P, Yang, Y, Cheemarla, NR, White, EB, Lapidus, S, Earnest, R, Geng, B, Vijayakumar, P, Odio, C, Fournier, J, Bermejo, S, Farhadian, S, Dela Cruz, CS, Iwasaki, A, Ko, AI, Landry, ML, Foxman, EF, Grubaugh, ND (B32) 2020; 5 Güven, E, Duus, K, Lydolph, MC, Jørgensen, CS, Laursen, I, Houen, G (B11) 2014; 403 Yan, Y, Chang, L, Wang, L (B38) 2020; 30 Mathur, G, Mathur, S (B5) 2020; 154 B25 B26 Charlton, CL, Kanji, JN, Johal, K, Bailey, A, Plitt, SS, MacDonald, C, Kunst, A, Buss, E, Burnes, LE, Fonseca, K, Berenger, BM, Schnabl, K, Hu, J, Stokes, W, Zelyas, N, Tipples, G (B21) 2020; 58 West, CP, Montori, VM, Sampathkumar, P (B4) 2020; 95 Sharpe, HR, Gilbride, C, Allen, E, Belij‐Rammerstorfer, S, Bissett, C, Ewer, K, Lambe, T (B40) 2020; 160 Amanat, F, Krammer, F (B33) 2020; 52 Yang, J, Petitjean, SJL, Koehler, M, Zhang, Q, Dumitru, AC, Chen, W, Derclaye, S, Vincent, SP, Soumillion, P, Alsteens, D (B28) 2020; 11 Mullard, A (B41) 2020; 395 Lee, CS, Belfort, G (B10) 1989; 86 Salathé, M, Althaus, CL, Neher, R, Stringhini, S, Hodcroft, E, Fellay, J, Zwahlen, M, Senti, G, Battegay, M, Wilder-Smith, A, Eckerle, I, Egger, M, Low, N (B2) 2020; 150 Lisoba Bastos, M, Tavaziva, G, Abidi, SK, Campbell, JR, Haraoui, L-P, Johnston, JC, Lan, Z, Law, S, MacLean, E, Trajman, A, Menzies, D, Benedetti, A, Ahmad Khan, F (B7) 2020; 370 Tan, CW, Chia, WN, Qin, X, Liu, P, Chen, MI-C, Tiu, C, Hu, Z, Chen, VC-W, Young, BE, Sia, WR, Tan, Y-J, Foo, R, Yi, Y, Lye, DC, Anderson, DE, Wang, L-F (B16) 2020; 38 Cao, Z, Liu, L, Du, L, Zhang, C, Jiang, S, Li, T, He, Y (B17) 2010; 7 Hotez, PJ, Corry, DB, Strych, U, Bottazzi, ME (B35) 2020; 20 Pinto, D, Park, Y-J, Beltramello, M, Walls, AC, Tortorici, MA, Bianchi, S, Jaconi, S, Culap, K, Zatta, F, De Marco, A, Peter, A, Guarino, B, Spreafico, R, Cameroni, E, Case, JB, Chen, RE, Havenar-Daughton, C, Snell, G, Telenti, A, Virgin, HW, Lanzavecchia, A, Diamond, MS, Fink, K, Veesler, D, Corti, D (B36) 2020; 583 Cao, Y, Su, B, Guo, X, Sun, W, Deng, Y, Bao, L, Zhu, Q, Zhang, X, Zheng, Y, Geng, C, Chai, X, He, R, Li, X, Lv, Q, Zhu, H, Deng, W, Xu, Y, Wang, Y, Qiao, L, Tan, Y, Song, L, Wang, G, Du, X, Gao, N, Liu, J, Xiao, J, Su, X-D, Du, Z, Feng, Y, Qin, C, Qin, C, Jin, R, Xie, XS (B9) 2020; 182 Younes, N, Al-Sadeq, DW, Al-Jighefee, H, Younes, S, Al-Jamal, O, Daas, HI, Yassine, HM, Nasrallah, GK (B20) 2020; 12 Tai, W, Zhang, X, He, Y, Jiang, S, Du, L (B37) 2020; 179 Crawford, KHD, Eguia, R, Dingens, AS, Loes, AN, Malone, KD, Wolf, CR, Chu, HY, Tortorici, MA, Veesler, D, Murphy, M, Pettie, D, King, NP, Balazs, AB, Bloom, JD (B39) 2020; 12 Perera, RAPM, Ko, R, Tsang, OTY, Hui, DSC, Kwan, MYM, Brackman, CJ, To, EMW, Yen, H-L, Leung, K, Cheng, SMS, Chan, KH, Chan, KCK, Li, K-C, Saif, L, Barrs, VR, Wu, JT, Sit, THC, Poon, LLM, Peiris, M (B19) 2021; 59 Zhou, P, Yang, XL, Wang, XG, Hu, B, Zhang, L, Zhang, W, Si, HR, Zhu, Y, Li, B, Huang, CL, Chen, HD, Chen, J, Luo, Y, Guo, H, Jiang, RD, Liu, MQ, Chen, Y, Shen, XR, Wang, X, Zheng, XS, Zhao, K, Chen, QJ, Deng, F, Liu, LL, Yan, B, Zhan, FX, Wang, YY, Xiao, GF, Shi, ZL (B18) 2020; 579 Wu, K, Chen, L, Peng, G, Zhou, W, Pennell, CA, Mansky, LM, Geraghty, RJ, Li, F (B27) 2011; 85 Salje, H, Rodríguez-Barraquer, I, Rainwater-Lovett, K, Nisalak, A, Thaisomboonsuk, B, Thomas, SJ, Fernandez, S, Jarman, RG, Yoon, I-K, Cummings, DAT (B42) 2014; 8 de Thier, P, Bacharouche, J, Duval, JFL, Skali-Lami, S, Francius, G (B14) 2015; 1854 Premkumar, L, Segovia-Chumbez, B, Jadi, R, Martinez, DR, Raut, R, Markmann, A, Cornaby, C, Bartelt, L, Weiss, S, Park, Y, Edwards, CE, Weimer, E, Scherer, EM, Rouphael, N, Edupuganti, S, Weiskopf, D, Tse, LV, Hou, YJ, Margolis, D, Sette, A, Collins, MH, Schmitz, J, Baric, RS, de Silva, AM (B8) 2020; 5 (B23) 2020 Lee, SH (B30) 2020; 2 Whitman, JD, Hiatt, J, Mowery, CT, Shy, BR, Yu, R, Yamamoto, TN, Rathore, U, Goldgof, GM, Whitty, C, Woo, JM, Gallman, AE, Miller, TE, Levine, AG, Nguyen, DN, Bapat, SP, Balcerek, J, Bylsma, SA, Lyons, AM, Li, S, Wong, AW-Y, Gillis-Buck, EM, Steinhart, ZB, Lee, Y, Apathy, R, Lipke, MJ, Smith, JA, Zheng, T, Boothby, IC, Isaza, E, Chan, J, Acenas, DD, Lee, J, Macrae, TA, Kyaw, TS, Wu, D, Ng, DL, Gu, W, York, VA, Eskandarian, HA, Callaway, PC, Warrier, L, Moreno, ME, Levan, J, Torres, L, Farrington, LA, Loudermilk, RP, Koshal, K, Zorn, KC, Garcia-Beltran, WF, Yang, D (B24) 2020; 38 Sethuraman, A, Belfort, G (B13) 2005; 88 Jackson, LA, Anderson, EJ, Rouphael, NG, Roberts, PC, Makhene, M, Coler, RN, McCullough, MP, Chappell, JD, Denison, MR, Stevens, LJ, Pruijssers, AJ, McDermott, A, Flach, B, Doria-Rose, NA, Corbett, KS, Morabito, KM, O’Dell, S, Schmidt, SD, Swanson, PA, Padilla, M, Mascola, JR, Neuzil, KM, Bennett, H, Sun, W, Peters, E, Makowski, M, Albert, J, Cross, K, Buchanan, W, Pikaart-Tautges, R, Ledgerwood, JE, Graham, BS, Beigel, JH (B34) 2020; 383 Krüttgen, A, Cornelissen, CG, Dreher, M, Hornef, M, Imöhl, M, Kleines, M (B22) 2020; 128 Pas, SD, Patel, P, Reusken, C, Domingo, C, Corman, VM, Drosten, C, Dijkman, R, Thiel, V, Nowotny, N, Koopmans, MP, Niedrig, M (B31) 2015; 69 Kyhlstedt, M, Andersson, SW (B3) 2020; 9 Mannik, M, Kapil, S, Merrill, CE (B15) 1997; 158 Lee, WT, Girardin, RC, Dupuis, AP, Kulas, KE, Payne, AF, Wong, SJ, Arinsburg, S, Nguyen, FT, Mendu, DR, Firpo-Betancourt, A, Jhang, J, Wajnberg, A, Krammer, F, Cordon-Cardo, C, Amler, S, Montecalvo, M, Hutton, B, Taylor, J, McDonough, KA (B43) 2021; 223 Tan, SS, Saw, S, Chew, KL, Huak, CY, Khoo, C, Pajarillaga, A, Wang, W, Tambyah, P, Ong, L, Jureen, R, Sethi, SK (B29) 2020; 52 Tom, MR, Mina, MJ (B6) 2020; 71 |
| References_xml | – volume-title: CRC TR 224 Discussion Paper Series crctr224_2020_175v1 year: 2020 ident: e_1_3_1_2_2 – volume: 158 start-page: 1446 year: 1997 ident: e_1_3_1_16_2 article-title: In patients with rheumatoid arthritis IgG binding to denatured collagen type II is in part mediated by IgG-fibronectin complexes publication-title: J Immunol doi: 10.4049/jimmunol.158.3.1446 – ident: e_1_3_1_26_2 doi: 10.1101/2020.06.26.173765 – ident: e_1_3_1_6_2 doi: 10.1093/ajcp/aqaa082 – ident: e_1_3_1_33_2 doi: 10.1038/s41564-020-0761-6 – ident: e_1_3_1_36_2 doi: 10.1038/s41577-020-0358-6 – ident: e_1_3_1_42_2 doi: 10.1016/S0140-6736(20)31252-6 – ident: e_1_3_1_7_2 doi: 10.1093/cid/ciaa619 – ident: e_1_3_1_39_2 doi: 10.1002/rmv.2106 – volume: 2 start-page: 69 year: 2020 ident: e_1_3_1_31_2 article-title: Testing for SARS-CoV-2 in cellular components by routine nested RT-PCR followed by DNA sequencing publication-title: Int J Geriatr Rehabil – ident: e_1_3_1_8_2 doi: 10.1136/bmj.m2516 – ident: e_1_3_1_17_2 doi: 10.1038/s41587-020-0631-z – ident: e_1_3_1_28_2 doi: 10.1128/JVI.02274-10 – ident: e_1_3_1_9_2 doi: 10.1126/sciimmunol.abc8413 – ident: e_1_3_1_41_2 doi: 10.1111/imm.13222 – ident: e_1_3_1_29_2 doi: 10.1038/s41467-020-18319-6 – ident: e_1_3_1_23_2 doi: 10.1016/j.jcv.2020.104394 – ident: e_1_3_1_25_2 doi: 10.1038/s41587-020-0659-0 – ident: e_1_3_1_11_2 doi: 10.1073/pnas.86.21.8392 – ident: e_1_3_1_34_2 doi: 10.1016/j.immuni.2020.03.007 – ident: e_1_3_1_13_2 doi: 10.1021/la903769c – ident: e_1_3_1_12_2 doi: 10.1016/j.jim.2013.11.014 – ident: e_1_3_1_35_2 doi: 10.1056/NEJMoa2022483 – ident: e_1_3_1_38_2 doi: 10.1016/j.antiviral.2020.104820 – ident: e_1_3_1_15_2 doi: 10.1016/j.bbapap.2014.12.001 – ident: e_1_3_1_5_2 doi: 10.1016/j.mayocp.2020.04.004 – ident: e_1_3_1_14_2 doi: 10.1529/biophysj.104.051797 – ident: e_1_3_1_22_2 doi: 10.1128/JCM.01361-20 – ident: e_1_3_1_43_2 doi: 10.1371/journal.pntd.0002952 – ident: e_1_3_1_18_2 doi: 10.1186/1743-422X-7-299 – volume-title: Interim guidelines for COVID-19 antibody testing. year: 2020 ident: e_1_3_1_24_2 – ident: e_1_3_1_27_2 doi: 10.1101/2020.07.31.230730 – ident: e_1_3_1_40_2 doi: 10.3390/v12050513 – ident: e_1_3_1_44_2 doi: 10.1093/infdis/jiaa673 – ident: e_1_3_1_10_2 doi: 10.1016/j.cell.2020.05.025 – ident: e_1_3_1_21_2 doi: 10.3390/v12060582 – ident: e_1_3_1_20_2 doi: 10.1128/JCM.02504-20 – ident: e_1_3_1_30_2 doi: 10.1016/j.pathol.2020.09.007 – ident: e_1_3_1_32_2 doi: 10.1016/j.jcv.2015.05.022 – ident: e_1_3_1_3_2 doi: 10.4414/smw.2020.20225 – ident: e_1_3_1_19_2 doi: 10.1038/s41586-020-2012-7 – ident: e_1_3_1_4_2 doi: 10.1016/j.hlpt.2020.04.010 – ident: e_1_3_1_37_2 doi: 10.1038/s41586-020-2349-y – volume: 7 start-page: 299 year: 2010 ident: B17 article-title: Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients publication-title: Virol J doi: 10.1186/1743-422X-7-299 – volume: 52 start-page: 583 year: 2020 end-page: 589 ident: B33 article-title: SARS-CoV-2 vaccines: status report publication-title: Immunity doi: 10.1016/j.immuni.2020.03.007 – volume: 179 start-page: 104820 year: 2020 ident: B37 article-title: Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2020.104820 – volume: 1854 start-page: 138 year: 2015 end-page: 145 ident: B14 article-title: Atomic force microscopy analysis of IgG films at hydrophobic surfaces: a promising method to probe IgG orientations and optimize ELISA tests performance publication-title: Biochim Biophys Acta doi: 10.1016/j.bbapap.2014.12.001 – volume: 395 start-page: 1751 year: 2020 end-page: 1752 ident: B41 article-title: COVID-19 vaccine development pipeline gears up publication-title: Lancet doi: 10.1016/S0140-6736(20)31252-6 – volume: 86 start-page: 8392 year: 1989 end-page: 8396 ident: B10 article-title: Changing activity of ribonuclease A during adsorption: a molecular explanation publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.86.21.8392 – volume: 69 start-page: 81 year: 2015 end-page: 85 ident: B31 article-title: First international external quality assessment of molecular diagnostics for Mers-CoV publication-title: J Clin Virol doi: 10.1016/j.jcv.2015.05.022 – volume: 579 start-page: 270 year: 2020 end-page: 273 ident: B18 article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin publication-title: Nature doi: 10.1038/s41586-020-2012-7 – volume: 150 start-page: w20225 year: 2020 ident: B2 article-title: COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation publication-title: Swiss Med Wkly doi: 10.4414/smw.2020.20225 – volume: 383 start-page: 1920 year: 2020 end-page: 1931 ident: B34 article-title: An mRNA vaccine against SARS-CoV-2—preliminary report publication-title: New Engl J Med doi: 10.1056/NEJMoa2022483 – volume: 88 start-page: 1322 year: 2005 end-page: 1333 ident: B13 article-title: Protein structural perturbation and aggregation on homogeneous surfaces publication-title: Biophys J doi: 10.1529/biophysj.104.051797 – volume: 158 start-page: 1446 year: 1997 end-page: 1452 ident: B15 article-title: In patients with rheumatoid arthritis IgG binding to denatured collagen type II is in part mediated by IgG-fibronectin complexes publication-title: J Immunol – ident: B25 article-title: Henderson R , Edwards RJ , Mansouri K , Janowska K , Stalls V , Kopp M , Haynes BF , Acharya P . 2020 . Glycans on the SARS-CoV-2 spike control the receptor binding domain conformation . bioRxiv https://doi.org/10.1101/2020.06.26.173765 . – volume: 95 start-page: 1127 year: 2020 end-page: 1129 ident: B4 article-title: COVID-19 testing: the threat of false-negative results publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2020.04.004 – volume: 30 year: 2020 ident: B38 article-title: Laboratory testing of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 (2019‐nCoV): current status, challenges, and countermeasures publication-title: Rev Med Virol doi: 10.1002/rmv.2106 – volume: 71 start-page: 2252 year: 2020 end-page: 2254 ident: B6 article-title: To interpret the SARS-CoV-2 test, consider the cycle threshold value publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa619 – volume: 370 start-page: m2516 year: 2020 ident: B7 article-title: Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis publication-title: BMJ doi: 10.1136/bmj.m2516 – volume: 58 year: 2020 ident: B21 article-title: Evaluation of six commercial mid- to high-volume antibody and six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies publication-title: J Clin Microbiol doi: 10.1128/JCM.01361-20 – year: 2020 ident: B1 article-title: An economic model of the Covid-19 epidemic: the importance of testing and age-specific policies publication-title: CRC TR 224 Discussion Paper Series crctr224_2020_175v1 ;University of Bonn and University of Mannheim ;Germany – volume: 5 year: 2020 ident: B8 article-title: The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients publication-title: Sci Immunol doi: 10.1126/sciimmunol.abc8413 – volume: 9 start-page: 126 year: 2020 end-page: 128 ident: B3 article-title: Diagnostic and digital solutions to address the COVID-19 pandemic: the need for international collaboration to close the gap publication-title: Health Policy Technol doi: 10.1016/j.hlpt.2020.04.010 – volume: 182 start-page: 73 year: 2020 end-page: 84.e16 ident: B9 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 2 start-page: 69 year: 2020 end-page: 96 ident: B30 article-title: Testing for SARS-CoV-2 in cellular components by routine nested RT-PCR followed by DNA sequencing publication-title: Int J Geriatr Rehabil – volume: 5 start-page: 1299 year: 2020 end-page: 1305 ident: B32 article-title: Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets publication-title: Nat Microbiol doi: 10.1038/s41564-020-0761-6 – volume: 12 start-page: 513 year: 2020 ident: B39 article-title: Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays publication-title: Viruses doi: 10.3390/v12050513 – volume: 52 start-page: 770 year: 2020 end-page: 777 ident: B29 article-title: Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays publication-title: Pathology doi: 10.1016/j.pathol.2020.09.007 – volume: 128 start-page: 104394 year: 2020 ident: B22 article-title: Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG publication-title: J Clin Virol doi: 10.1016/j.jcv.2020.104394 – volume: 583 start-page: 290 year: 2020 end-page: 295 ident: B36 article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody publication-title: Nature doi: 10.1038/s41586-020-2349-y – volume: 160 start-page: 223 year: 2020 end-page: 232 ident: B40 article-title: The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world publication-title: Immunology doi: 10.1111/imm.13222 – volume: 223 start-page: 47 year: 2021 end-page: 57 ident: B43 article-title: Neutralizing antibody responses in COVID-19 convalescent sera publication-title: J Infect Dis doi: 10.1093/infdis/jiaa673 – volume: 59 year: 2021 ident: B19 article-title: Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera publication-title: J Clin Microbiol doi: 10.1128/JCM.02504-20 – volume: 38 start-page: 1174 year: 2020 end-page: 1183 ident: B24 article-title: Evaluation of SARS-CoV-2 serology assays reveals a range of test performance publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0659-0 – ident: B26 article-title: Cao W , Dong C , Kim S , Hou D , Tai W , Du L , Im W , Zhang XF . 2020 . Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction . bioRxiv https://doi.org/10.1101/2020.07.31.230730 . – volume: 20 start-page: 399 year: 2020 end-page: 400 ident: B35 article-title: COVID-19 vaccines: neutralizing antibodies and the alum advantage publication-title: Nat Rev Immunol doi: 10.1038/s41577-020-0358-6 – volume: 38 start-page: 1073 year: 2020 end-page: 1078 ident: B16 article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0631-z – volume: 12 start-page: 582 year: 2020 ident: B20 article-title: Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2 publication-title: Viruses doi: 10.3390/v12060582 – volume: 85 start-page: 5331 year: 2011 end-page: 5337 ident: B27 article-title: A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses publication-title: J Virol doi: 10.1128/JVI.02274-10 – volume: 26 start-page: 5679 year: 2010 end-page: 5689 ident: B12 article-title: Protein adsorption on a hydrophobic surface: a molecular dynamics study of lysozyme on graphite publication-title: Langmuir doi: 10.1021/la903769c – volume: 8 year: 2014 ident: B42 article-title: Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0002952 – year: 2020 ident: B23 publication-title: Interim guidelines for COVID-19 antibody testing. ;Centers for Disease Control and Prevention ;Atlanta, GA – volume: 11 start-page: 4541 year: 2020 ident: B28 article-title: Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor publication-title: Nat Commun doi: 10.1038/s41467-020-18319-6 – volume: 403 start-page: 26 year: 2014 end-page: 36 ident: B11 article-title: Non-specific binding in solid phase immunoassays for autoantibodies correlates with inflammation markers publication-title: J Immunol Methods doi: 10.1016/j.jim.2013.11.014 – volume: 154 start-page: 1 year: 2020 end-page: 3 ident: B5 article-title: Antibody testing for COVID-19: can it be used as a screening tool in areas with low prevalence? publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqaa082 |
| SSID | ssj0014455 |
| Score | 2.6192925 |
| Snippet | Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody... |
| SourceID | pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Virology |
| Title | A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33500361 https://journals.asm.org/doi/10.1128/JCM.02438-20 https://www.proquest.com/docview/2481638069 https://pubmed.ncbi.nlm.nih.gov/PMC8092720 |
| Volume | 59 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLdgCMQFwfgqXzIITlVG6rhuwq0rm6ZpLYi2qLfITmKtUpuiNj1s_PO8Z8dJy1ppcIkqx3XavJ-f3_cj5KNgssOA93qad6THAUOeaqepF-gwggMt5cJ4dPsDcTbm55P2pLYqmeySQh0l1zvzSv6HqjAGdMUs2X-gbLUoDMBnoC9cgcJwvRWNuyY8cdj9MfR6i58ea35dy5n3Hd4dRqEDG7AFlkbA-VHzx5iO2RU2iFhjgQjgDTYQK8cS54nLVhxka2P9uDYGk7yYqkWKgrqJpcUoo8J-aY9YW6Vazqd1jaeb9oEhegB6NaiWNvfk2AaYuYiDpet53ZPLeZY3K0v1sZyWxvbu6tL5pkvjBTPRWyWLtPwWy5kK4U_scbRjrGTS7WgDjHw372eYz3De6x9hlUVESn3GOb_-4Ft8Or64iEcnk9Fdco-BbsGciad0PXFuWuVWv8JlS7Dw8-bacITL1ZxtizM3dJS_Q203ZJfRY_KopA7tWgQ9IXey_JDct21Irw7Jg34ZYPGU_O5SgBStIUU3IUUdpChC6gu1gKIOULQCFC0BRQFQdBNQ1AGKOkDRClDPyPj0ZNQ788r-HJ7kIS-8FE6DgMHWbvFMpUIrEEajVGuNmUHtDG4o-N8qyATzZSvVPAJdQmRctqQWgqfBc3KQL_LsJaEdrVoJ50LqQPCE-aGGtdodpRJfZpFWDfIB33Zcbr5VbHRXFsZAktiQJGZ-gzQdLeKkrHCPjVZme2Z_qmb_spVd9sx778gaA-tFf5rMs8V6FTMeojbji6hBXlgyVysFQRtLPbUapLMFgGoClnXfvpNPL01599CPMDji1S2e-5o8rHfVG3JQLNfZWxCSC_XOgPoPQ5m-OQ |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+New+SARS-CoV-2+Dual-Purpose+Serology+Test%3A+Highly+Accurate+Infection+Tracing+and+Neutralizing+Antibody+Response+Detection&rft.jtitle=Journal+of+clinical+microbiology&rft.au=Taylor%2C+Sean+C&rft.au=Hurst%2C+Beth&rft.au=Charlton%2C+Carmen+L&rft.au=Bailey%2C+Ashley&rft.date=2021-03-19&rft.issn=1098-660X&rft.eissn=1098-660X&rft.volume=59&rft.issue=4&rft_id=info:doi/10.1128%2FJCM.02438-20&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0095-1137&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0095-1137&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0095-1137&client=summon |